Jim Cramer, host of Mad Money, recently emphasized the importance of long-term investing, urging investors to focus on the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo NOrdisk (NVO) stock drops as Medicare selects 15 additional Part D drugs including its weight loss drug Wegovy for ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

GLP-1 drugs like Ozempic became so popular as weight loss drugs that there was a mid-year shortage. These drugs are also ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...